echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > The State Food and Drug Administration approves Hengrui Pharmaceuticals Pregabalin Sustained-Release Tablets for the treatment of chronic neuropathic pain in adults

    The State Food and Drug Administration approves Hengrui Pharmaceuticals Pregabalin Sustained-Release Tablets for the treatment of chronic neuropathic pain in adults

    • Last Update: 2021-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 28, the official website of the National Food and Drug Administration (NMPA) announced that the pregabalin sustained-release tablets declared by Hengrui Medicine had been approved for listing in China


    Pregabalin is an analogue of the neurotransmitter γ-aminobutyric acid (GABA).


    FDA Diabetes Epilepsy Management


    The dosage form declared by Hengrui Medicine is pregabalin sustained-release tablets




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.